0001689375-23-000044.txt : 20230623
0001689375-23-000044.hdr.sgml : 20230623
20230623162025
ACCESSION NUMBER: 0001689375-23-000044
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230621
FILED AS OF DATE: 20230623
DATE AS OF CHANGE: 20230623
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: WENTWORTH KORY JAMES
CENTRAL INDEX KEY: 0001725663
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40969
FILM NUMBER: 231037965
MAIL ADDRESS:
STREET 1: 6 TIDE STREET
STREET 2: C/O ENTRADA THERAPEUTICS
CITY: BOSTON
STATE: MA
ZIP: 02210
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Entrada Therapeutics, Inc.
CENTRAL INDEX KEY: 0001689375
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 813983399
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE DESIGN CENTER PLACE
STREET 2: SUITE 17-500
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 857-305-1825
MAIL ADDRESS:
STREET 1: ONE DESIGN CENTER PLACE
STREET 2: SUITE 17-500
CITY: BOSTON
STATE: MA
ZIP: 02210
FORMER COMPANY:
FORMER CONFORMED NAME: CycloPorters, Inc.
DATE OF NAME CHANGE: 20161104
4
1
wf-form4_168755161282030.xml
FORM 4
X0407
4
2023-06-21
0
0001689375
Entrada Therapeutics, Inc.
TRDA
0001725663
WENTWORTH KORY JAMES
C/O ENTRADA THERAPEUTICS, INC.
ONE DESIGN CENTER PLACE, SUITE 17-500
BOSTON
MA
02210
0
1
0
0
Chief Financial Officer
1
Common Stock
2023-06-21
4
M
0
17500
2.10
A
45457
D
Common Stock
2023-06-21
4
S
0
8593
14.8399
D
36864
D
Common Stock
2023-06-21
4
S
0
8907
15.1711
D
27957
D
Stock Option (Right to Buy)
2.1
2023-06-21
4
M
0
17500
0
D
2030-11-10
Common Stock
17500.0
83447
D
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.05 to $15.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.05 to $15.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
25% of the shares subject to this option shall vest and become exercisable on November 16, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.
/s/ Jared Cohen, as Attorney-in-Fact
2023-06-23